A n association between endotoxin and cholestasis is well established. The clinical condition in which this has been reported most widely is sepsis. Estimates for frequency of cholestasis in sepsis have varied from ~1% to over 50%, depending on such factors as the study population and diagnostic criteria.
A n association between endotoxin and cholestasis is well established. The clinical condition in which this has been reported most widely is sepsis. Estimates for frequency of cholestasis in sepsis have varied from ~1% to over 50%, depending on such factors as the study population and diagnostic criteria.
(1) However, several studies suggest that frequency of cholestasis in severe sepsis is in the 20%-30% range. (2, 3) Endotoxin is thought to be important in the pathogenesis of alcoholic hepatitis (AH) as well. (4) Although this had been considered a disease that mostly reflects inflammatory damage to hepatocytes, evolving evidence suggests that cholestasis can also be an important component of AH, and, in fact, the presence of cholestasis may reflect more-severe disease. (5) (6) (7) The molecular basis for endotoxin-induced cholestasis has been examined mostly in hepatocytes and has been attributed to decreased expression of several transporters that are important for canalicular bile formation. (8) (9) (10) However, bile secretion depends not only upon formation of primary canalicular bile by hepatocytes, but also upon further conditioning of bile by cholangiocytes. (11) Yet, very little is known about the effects of endotoxin on cholangiocyte secretion.
A variety of diseases affecting cholangiocytes result in cholestasis. Despite different etiologies, primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), biliary atresia, and biliary obstruction each furthermore is associated with loss of the type 3 inositol 1,4,5-trisphosphate receptor (ITPR3) from cholangiocytes. (12) Knockdown of ITPR3 in cholangiocytes specifically inhibits bicarbonate and fluid secretion, (13) suggesting that its loss in these different cholangiopathies may represent a final common pathway to cholestasis. Certain transcription factors (14) and micro-RNAs (15) can decrease ITPR3 expression in cholangiocytes, but the role of these may differ among the various cholangiopathies. The purpose of this study was to investigate whether and how endotoxin inhibits ITPR3 expression in human cholangiocytes and determine the clinical relevance of this.
Materials and Methods

aNalySIS oF NF-κB BINDINg SIteS aND tRaNSFeCtIoN
MatInspector (www.genomatix.de) was used to analyze the human ITPR3 promoter sequence, and five putative elements responding to nuclear factor-κB (NF-κB) were identified. For generation of fusion plasmids with firefly luciferase, 2-, 1-, and 0.5-kilobase (kb) 5′-upstream regions of the human ITPR3 gene, including the proximal promoter, were cloned. Normal human cholangiocyte (NHC) cells were cotransfected with each of the ITPR3 promoter (ITPR3pr) fragment and plasmids encoding p65 and p50 subunits of NF-κB with or without IκB-α super suppressor (IκBSR). Luciferase activity was analyzed 48 hours later using the Dual Luciferase kit (Promega, Madison, WI) Also, NHC cells were treated with lipopolysaccharide (LPS; 1 µg/mL) for 18 hours, after transfection with ITPR3pr 2 kb. In all experiments, NHC cells were cotransfected with Renilla luciferase plasmid to normalize for transfection efficiency. Sitedirected mutants of the ITPR3 promoter reporter constructs were generated using the QuickChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, CA), according to the manufacturer's instructions. Mutated NF-κB constructs comprised five NF-κB single mutated plasmids (ITPR3-mut-NFκB1, ITPR3-mut-NFκB2, ITPR3-mut-NFκB3, ITPR3-mut-NFκB4, and ITPR3-mut-NFκB5), and the specific primers are listed in Supporting Table S3 . Mutated reporter constructs were verified by DNA sequencing at the W.M. Keck Biotechnology Resource Laboratory at Yale University (New Haven, CT).
lysates were prepared with isolation buffer. Chromatin samples were sheared into fragments by sonication followed by centrifugation at 10,000 rpm for 10 minutes at 4°C. Sheared chromatin samples were precleared using protein G beads, then incubated overnight at 4°C with chromatin immunoprecipitation (ChIP)-grade rabbit anti-NF-κB p65 monoclonal antibody (Abcam, Cambridge, MA). Anti-H3K9me or normal rabbit immunoglobulin G (IgG) were used as negative controls. DNA was purified, and real-time PCR was performed to evaluate ChIP-enriched DNA. (14) IoN CalCIUM MeaSUReMeNtS NHC cells were plated onto glass coverslips 24 hours before imaging. Cells were then loaded with 6 µM of Fluo-4/AM (Invitrogen, Eugene, OR) for 30 minutes at 37°C. Once transferred to a custom-built perfusion chamber on the stage of a Zeiss LSM 710 confocal microscope (Carl Zeiss, Inc., Thornwood, NY), cells were perfused with HEPES buffer (16) 
StatIStICal aNalySIS
Results are presented as mean ± SEM. Data were analyzed using GraphPad Prism software (version 7; GraphPad Software, La Jolla, CA) and Microsoft Excel (Microsoft Corporation, Redmond, WA). Differences between experimental groups were assessed for significance using the Student t test or one-way analysis of variance (ANOVA) followed by Bonferroni post-hoc tests. Statistical significance was defined as P < 0.05.
FURtHeR MetHoDologICal DetaIlS
Detailed additional Materials and Methods are available in the Supporting Information.
Results
lpS DeCReaSeS ItpR3 eXpReSSIoN
Because ITPR3 is the principal ITPR isoform in cholangiocytes and is important for bicarbonate-rich secretion, (12, 13, 18) the effect of LPS on ITPR3 expression was tested in NHC cells. ITPR3 mRNA expression was reduced in cells treated with LPS concentrations of 125 (0.20 ± 0.05; P < 0.001; n = 5), 250 (0.30 ± 0.01; P < 0.001; n = 5), and 500 ng/mL (0.27 ± 0.01; P < 0.001; n = 5), when compared to control (Fig. 1A ). This decrease was not observed at lower LPS concentrations of 31 (0.86 ± 0.07; n = 3) or 62 ng/mL (0.93 ± 0.03; n = 3). Because 125 ng/mL was the lowest LPS concentration to maximally inhibit ITPR3 expression, this concentration was used for further studies. To determine whether the LPS-mediated decrease in ITPR3 expression was time dependent, cells were treated with LPS (125 ng/mL) for 30 minutes and 6 and 18 hours. ITPR3 mRNA levels progressively decreased over time, reaching its lowest level at 18 hours (Fig. 1B) . ITPR3 protein levels were also reduced in NHC cells exposed to LPS for 18 hours as shown by both western blotting (control 0.34 ± 0.03 vs. LPS 0.14 ± 0.03; p < 0.01; n = 3; Fig.  1C ) and immunofluorescence (IF; control 38.78 ± 5.40 vs. LPS 17.74 ± 0.77; n = 3; 15 cells for each group; P < 0.01; Fig. 1D ). Similar findings were obtained in H69 cells, in which exposure to LPS reduced both ITPR3 mRNA (control, 1.00 ± 0.02; LPS, 0.55 ± 0.07; P < 0.05; n = 3; Fig. 1E ) and protein expression (control, 0.64 ± 0.06; LPS, 0.13 ± 0.05; P < 0.05; n = 3; Fig. 1F ) when compared to untreated control cells. We also evaluated whether the expression of the two minor isoforms of the ITPR in cholangiocytes, ITPR1 and ITPR2, (13, 18) is altered by LPS treatment. Real-time PCR analysis showed that treatment of NHC cells with LPS resulted in a much lesser, but nonetheless significant, decrease of ITPR1 mRNA (0.68 ± 0.03; P < 0.001; n = 5) compared to control, whereas no alteration in ITPR2 was observed (0.88 ± 0.08; n = 5) relative to untreated control cells (Supporting Fig.  S1 ). These results are similar to what was observed in a rat model of endotoxemia, (12) and together suggest that LPS treatment down-regulates ITPR3 expression in human cholangiocytes as well.
NF-κB INHIBItS ITPR3 pRoMoteR aCtIVIty
Endotoxins typically activate the transcription factor, NF-κB, by binding to Toll-like receptor 4 (TLR4), (19) which is expressed in cholangiocytes. (20) The NF-κB inhibitor, BAY 11-7082 (BAY), prevented the decrease in ITPR3 that was induced by LPS in mRNA (LPS + BAY 0.80 ± 0.06 vs. LPS 0.35 ± 0.04; n = 3; P < 0.001; Fig. 2A ) and protein levels (LPS + BAY 0.77 ± 0.07 versus LPS 0.18 ± 0.09; P < 0.01; Fig.  2B ), suggesting a role for this pathway in regulating ITPR3 expression. Therefore, an in silico analysis of the proximal 2 kb of the human ITPR3 promoter was performed to probe for putative NF-κB-responsive elements. This revealed the presence of five potential NF-κB-responsive elements located at -293 to -307 base pairs (bp; NF-κB1), -329 to -343 bp (NF-κB2), -397 to -411 bp (NF-κB3), -860 to -874bp (NF-κB4), and -1,778 to -1,792 bp (NF-κB5) upstream Western blot for H3K9 methylation after LPS treatment (125 ng/mL, 18h) in NHC cells. *P < 0.05; **P < 0.01; ***P < 0.001, using one-way ANOVA test, followed by Bonferroni's post-hoc test. Abbreviation: GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
of the transcription starting sites (Supporting Fig.  S2 ). To validate the MatInspector software analyses, NHCs were initially transfected with a 2-kb fragment of the ITPR3 promoter fused with luciferase alone or in combination with p65/p50 plasmids or else treated with LPS (1 µg/mL; Supporting Fig. S3 ). Luciferase activity of the ITPR3 promoter construct was reduced by coexpression of NF-κB subunits (2 kb ITPR3pr 28.8 ± 2.9 vs. 2 kb ITPR3pr + p50/p65 14.6 ± 0.6; P < 0.05; n = 6; Fig. 2C ). Similar inhibition was found after LPS treatment (2 kb ITPR3pr 7.61 ± 0.46 vs. 2 kb ITPR3pr + LPS 5.78 ± 0.49; P < 0.05). Furthermore, cotransfection with IκBSR, an antagonist of NF-κB activity, rescued the p65/p50-induced inhibition of ITPR3 promoter activity (29.5 ± 4.4; n = 6). Next, NHC cells were transfected with nested deletion fragments of 1.0 and 0.5 kb containing the proximal conserved NF-κB elements and alongside with p65/p50 plasmids (Fig. 2D ). Both nested fragments showed inhibition by p65/p50 (1.0 kb ITPR3pr 70.1 ± 1.3 vs. 1.0 kb ITPR3pr + p50/p65 40.5 ± 0.9; P < 0.05; n = 3; and 0.5 kb ITPR3pr 48.5 ± 8.2 vs. 0.5 kb ITPR3pr + p50/p65 7.9 ± 0.2; P < 0.01; n = 3). To determine the relative importance of each putative NF-κB binding site on ITPR3 promoter activity, NF-κB mutants of each of the five sites (Supporting Fig. S2 ) were generated. Promoter activity of each of the five mutants was decreased by coexpression of p50/p65 (not shown). These results provide evidence that the proximal 2 kb of the human ITPR3 promoter contains functional NF-κB response elements, and that none of the five putative binding sites is dominant, although it is alternatively possible that the effect of NF-kB on the ITPR3 promoter is indirect. To investigate whether the inhibitory effect of NF-κB on ITPR3 promoter activity is attributed to direct binding of this transcription factor to the ITPR3 promoter, a ChIP assay was performed using a p65 antibody. p65 was recruited to the proximal NF-κB elements spanning the region between 270 and 490 bp (5.67 ± 0.28; P < 0.001; n = 3), and this recruitment was further induced in cells treated with LPS 125 ng/mL for 6 hours (10.1 ± 0.9; P < 0.01; n = 3), compared to nontreated controls (5.1 ± 0.1; n = 3; Fig. 2E ). Together, these findings provide evidence that NF-κB inhibits ITPR3 expression through direct binding to the ITPR3 promoter.
Because NF-κB binding reduces ITPR3 promoter activity, we evaluated whether this binding is associated with methylation of histone H3 at lysine 9 (H3K9), a well-known repressive epigenetic signature. (14) ChIP analysis showed that NHC cells cotransfected with the 2-kb ITPR3 promoter and p65/p50 plasmids displayed increased H3K9 methylation (3.30 ± 1.56; P < 0.05; n = 3), relative to the normal IgG control group (0.95 ± 0.60; n = 3; Fig. 2F ). Also, LPS treatment increased overall protein levels of methylated H3K9 (0.66 ± 0.02 vs. 0.38 ± 0.01; Fig. 2G ). These results suggest that p65/p50 reduces ITPR3 promoter activity by repressive epigenetic modifications at NF-κB binding sites.
tlR4 DeCReaSeS ItpR3 eXpReSSIoN By aCtIVatIoN oF NF-κB IN CHolaNgIoCyteS
To test whether NF-κB is involved in TLR4-dependent down-regulation of ITPR3, NF-κB expression, and localization were measured in NHC cells after LPS treatment. NF-κB mRNA (0.84 ± 0.02; n = 3) and protein levels (0.85 ± 0.04; n = 3) were not altered in LPS-treated cells, as compared to control proteins (0.96 ± 0.02; n = 3; Fig. 3A,B) . Next, NF-κB activation was assessed in three ways. First, phosphorylation of p65 was increased in LPStreated cells relative to controls (0.04 ± 0.004 vs. 0.02 ± 0.003; n = 3; P < 0.01; Fig. 3B ). Second, IF of p65 in NHC cells showed that p65 translocates to the nucleus after 6 hours of treatment with LPS (101.9 ± 8.75; 15 cells in each group; P < 0.01), compared to untreated controls (41.27 ± 78.63; n = 3; 15 cells for each group; Fig. 3C ). Finally, protein (Fig. 3D ) and mRNA expression levels (Supporting Fig. S4 ) of NF-κB-regulated interleukins (ILs) were measured. LPS treatment (125 ng/mL for 18 hours) increased IL-6 (164 ± 15.10 vs. 16.28 ± 1.46) and IL-8 (277.3 ± 6.41 vs. 23.77 ± 0.22) protein levels relative to controls (P < 0.001). Similarly, LPS treatment increased IL-8 mRNA (2.16 ± 0.26; P < 0.01; n = 4), but did not change IL-1 (0.75 ± 0.10; n = 4) or IL-6 levels (1.34 ± 0.02; n = 4). Treatment of NHC cells with the TLR4 antagonist, TAK242, prevented reduction in ITPR3 mRNA levels induced by LPS (0.90 ± 0.03; n = 3) as well as induction of the NF-κB target gene, IL-8 (1.30 ± 0.25; n = 3; Supporting Fig. S4 ). To validate the importance of TLR4 for LPS-dependent reduction of ITPR3 expression, TLR4 was silenced with small interfering RNA (siRNA) in NHC cells (Control + siTLR4 0.25 ± 0.02 versus Control 0.97 ± 0.24; Fig. 3F ). Upon TLR4 silencing, treatment of NHC cells with LPS no longer decreased ITPR3 mRNA expression (LPS + siTLR4 0.98 ± 0.08 vs. LPS 0.40 ± 0.07; Fig. 3F ). Next, ITPR3 expression in bile ducts was evaluated in WT and TLR4KO mouse livers 24 hours after treatment of mice with endotoxin. ITPR3 expression was reduced in WT mice treated with LPS relative to saline-treated controls, whereas ITPR3 expression was not decreased by LPS in TLR4KO mice (Fig. 3G) . Together, these results provide evidence that reduction of ITPR3 expression induced by LPS is mediated largely, if not entirely, by the TLR4/NF-κB pathway.
lpS atteNUateS Ca 2+ SIgNalINg IN CHolaNgIoCyteS
Because ITPR3 is the main intracellular calcium-release channel expressed in cholangiocytes, (18) we WT and TLR4 KO mice injected with saline or LPS (n = 3-6 bile ducts from 3 animals per condition). Scale bar = 10 µm. *P < 0.05; **P < 0.01; ***P < 0.001, using the Student t test (B) or one-way ANOVA test, followed by Bonferroni's post-hoc test (A, C and D -mediated bicarbonate secretion in cholangiocytes, (13) and amplitude of ATP-induced (1 µM) calcium signals was similar between untreated and LPS-treated NHC cells (428 ± 33% increase in fluo-4 fluorescence in LPS-treated cells vs. 509 ± 39% in controls; n = 3 preps with 30 cells in each group; Fig. 4C) . However, the percentage of responding cells was decreased in the LPS-treated group (29 ± 8%; P < 0.05) relative to controls (68 ± 7%; n = 3; 30 cells in each group). Furthermore, there was an increase in the fraction of responding cells with an oscillatory pattern in the LPS-treated group relative to untreated controls (62 ± 6% vs. 33 ± 4%, respectively; n = 3 preps with 30 cells in each group; P < 0.05); Ca 2+ oscillations represent a submaximal signaling response compared to sustained increases in calcium. (21, 22) Additionally, the rise time of Ca 2+ signals induced by photorelease of caged InsP3, which is inversely correlated with expression and activity of ITPR receptors, (23) was significantly faster in NHC cells overexpressing mCherry-ITPR3 that were treated with LPS when compared to nontransfected LPS-treated cells (LPS = 9.75 ± 2.02 seconds, n = 8 vs. LPS + mCherry ITPR3 = 2.5 ± 0.5 seconds, n = 10; P < 0.01; Fig. 4F,G) . Collectively, these results provide functional evidence that LPS-induced down-regulation of ITPR3 expression renders cells less responsive to Ca 2+ -releasing agonists, and that this defect can be rescued by reexpression of ITPR3. Because cAMP is a major determinant of bicarbonate secretion by cholangiocytes and LPS may stimulate cAMP in other cells systems, (24) cAMP production was compared between control and LPS-treated NHC cells. No difference between these two groups was found either under baseline (unstimulated) conditions or after treatment with Forskolin (Supporting Figure S8 ). These findings show that LPS-mediated decrease in ITPR3 is not accompanied by a compensatory production of cAMP.
ItpR3 eXpReSSIoN IS DeCReaSeD IN BIle DUCtS oF patIeNtS WItH ClINICal CoNDItIoNS aSSoCIateD WItH eNDotoXeMIa
To investigate the clinical relevance of these findings, IHC was performed in liver samples from patients with sepsis or AH, two conditions associated with endotoxemia. Liver samples from autopsies of patients with cholestasis-associated sepsis (Supporting Table  S1 ) were examined for p65, ITPR3, and TLR4 labeling (Fig. 5) . TLR4 expression appeared increased in sepsis samples, and labeling of p65 was detected in the nucleus of 27% of cholangiocytes in sepsis specimens (n = 226 cells), as compared to 7% of cholangiocytes in histologically normal liver tissues (n = 222 cells; P < 0.0001 by chi-squared test), suggesting that NF-κB is frequently activated in cholangiocytes in patients with sepsis (11 ducts in six sepsis specimens, eight ducts in five control specimens). Conversely, the apical ITPR3 staining observed in cholangiocytes in normal human liver (12, 18) was reduced in cholangiocytes of patients with sepsis (309 ± 52; n = 5; vs. 94 ± 20; n = 6, respectively; P < 0.01). Moreover, apical ITPR3 labeling inversely correlated with the percentage of cells with NF-κB in the nucleus (R 2 = 0.8693; ***P < 0.001). Liver specimens from AH were evaluated as an additional clinical condition of increased endotoxemia in which cholestasis is a manifestation. Analysis of laboratory data from 31 consecutive AH patients at Yale-New Haven Hospital that underwent liver biopsy to confirm the diagnosis showed that 23 of these individuals had elevated ALP levels (Supporting Table S2 ), consistent with cholestasis. ITPR3, p65, and TLR4 immunolocalization was performed in liver samples that were available from these patients. Similar to the findings in sepsis samples, TLR4 expression was increased and NF-кB was translocated to the nucleus in AH liver specimens (p65-positive nuclei in 3.5%, n = 301 cells from 4 control patients vs. 73.5%, n = 156 cells from 2 AH patients). Apical ITPR3 staining in cholangiocytes of seven AH livers was decreased relative to controls (121 ± 16 vs. 186 ± 20, respectively; P < 0.05; Fig. 6 ) and was inversely correlated with the percentage of p65-positive nuclei (R 2 = 0.6645; *P < 0.05). Notably, no increase in nuclear factor, erythroid 2-like 2 (Nrf2) staining was detected in either AH or sepsis cholangiocytes (Supporting Figs. S5 and S6) . Similarly, there was no significant change in Nrf2 mRNA in NHC cells after LPS treatment (Supporting Fig. S7 ). This transcription factor has been linked to decreased ITPR3 expression in other, more classical cholestatic disorders. (14) Taken together, these results support the idea that endotoxin down-regulates ITPR3 expression in human cholangiocytes. This may contribute to the mechanism by which conditions of endotoxemia result in cholestasis.
Discussion
A principal finding of the current study is that LPS binds to TLR4 on cholangiocytes to cause an NF-κB-mediated decrease in ITPR3 expression. This has several clinical implications. First, ITPR3 plays an important role in regulating bicarbonate secretion in cholangiocytes. It is most concentrated in a specialized region of the endoplasmic reticulum (ER) beneath the apical membrane, where it is positioned to release calcium to activate the calcium-dependent chloride channel, transmembrane member 16a, which, in turn, couples with the chloride-bicarbonate exchanger, anion exchanger 2, to result in net bicarbonate secretion. (25) This ITPR3 pool is effectively released by nucleotides in bile, which activate apical P2Y receptors, resulting in local formation of InsP3. (13) Although hepatocytes can secrete ATP into bile, (26, 27) activation of the cystic fibrosis transmembrane conductance regulator in Insets show enlarged view of the selected regions. Scale bar, 50 µm. TLR4 expression is increased in sepsis samples (first row). Bile duct cells positive for p65 in the nucleus were counted in blinded fashion (middle row). In sepsis, 27% of cholangiocytes were positive for nuclear p65 (n = 226 cholangiocytes) as opposed to 7% in control specimens (n = 222 cholangiocytes). Apical ITPR3 expression is reduced in cholangiocytes of patients with sepsis-associated cholestasis (bottom row). Left graph shows average intensity of apical ITPR3 staining in bile ducts from control and sepsis livers (n = 6 sepsis patients and 5 controls; **P < 0.01, by Student t test). Right graph shows the correlation between apical ITPR3 (intensity value) and percentage of p65-postivie nuclei (control = 3 and sepsis = 5). The linear regression curve (R 2 = 0.8693; ***P < 0.001) is indicated by the solid line with 95% confidence interval indicated by the dashed lines.
cholangiocytes may be an additional route by which this occurs. (28) Furthermore, ITPR3 expression is lost in a variety of human cholangiopathies, (12) and selective knockdown of ITPR3 inhibits biliary bicarbonate secretion as well. (13) Therefore, LPS-induced loss of ITPR3 from cholangiocytes may represent a previously unappreciated mechanism by which sepsis induces cholestasis. Second, in cells that coexpress multiple ITPR isoforms, ITPR3 is the isoform that preferentially couples to mitochondria and transmits apoptotic calcium signals into them. (29) Selective loss of ITPR3 reduces apoptosis, including in response to apoptotic stimuli such as bile acids. (29) Small, proliferating bile ductules are a common histological finding in obstructive cholestasis as well as in certain other cholangiopathies, (30) and loss of ITPR3 may permit these ductules to proliferate despite increased exposure to bile acids because of their decreased sensitivity to apoptotic stimuli. Moreover, ITPR3 is concentrated apically in both small and large ducts, (14) and we found that loss of ITPR3 was similar in both types of ducts in severe AH (not shown). Third, it has long been appreciated that chronic biliary infections or inflammation increases the risk of developing cholangiocarcinoma (CCA). (31) The current work is consistent with the idea that such conditions may also lead to chronic loss of ITPR3 in cholangiocytes. However, several investigators have reported that loss of ITPR3 can be a premalignant condition in cancers such as melanoma, mesothelioma, and prostate cancer. (32, 33) This effect also has been attributed to impaired mitochondrial calcium signaling and a resulting decrease in apoptosis. Further work will be needed to determine whether loss of ITPR3 from cholangiocytes attributed to LPS or other inflammatory conditions contributes not only to cholestasis, but also to ductular proliferation and ultimately to the development of CCA.
The current study also provides evidence that ITPR3 is lost in cholangiocytes of patients with several conditions of endotoxemia; sepsis and severe AH. The most immediate clinical effect of this would be cholestasis. Cholestasis has long been recognized as a complication of sepsis, (1) but most previous studies have focused on the effects of LPS on secretion by hepatocytes rather than cholangiocytes. (8, 9) Several studies have carefully delineated the loss of transporters, such as Na + -taurocholate cotransporting polypeptide (10, 34) and multidrug resistance-associated protein 2 (MRP2), (8) that occurs in response to LPS. There is also evidence that LPS reduces expression of ITPR2 in hepatocytes, (35) which plays an analogous role to ITPR3 in cholangiocytes. ITPR2 is the principal intracellular calcium-release channel in hepatocytes, and it is most concentrated in a specialized region of the ER beneath the canalicular membrane. (36, 37) It participates in targeting and insertion of MRP2 and bile salt export pump into the canalicular membrane, and its loss may participate in the pathogenesis of cholestasis. (23, 35) LPS also causes transient increases in NF-κB and activator protein 1 (AP-1) in hepatocytes. (38) Although there is little to no ITPR3 in normal hepatocytes (36) and it is not known whether NF-κB inhibits ITPR2 expression, there is recent evidence that AP-1 inhibits expression of ITPR2. (39) It had been reported that LPS decreases ITPR3 in cholangiocytes in a rodent model, (12) although the mechanism for this and the relevance in patients with cholestasis have not been examined. It also has been shown that inflammatory cytokines inhibit ductular secretion. (40) It is not known whether and to what extent this is also attributed to decreased expression of ITPR3 and, if so, whether cytokines mediate this effect through NF-κB, or else by the oxidant stress sensor, Nrf2, or microRNA 506, each of which have been shown to inhibit ITPR3 expression in other types of cholangiopathies. (14, 15) It is now widely accepted that endotoxin plays a major role in the development of AH. Its role is attributed mostly to immune activation and consequent damage to hepatocytes. (41) There is an evolving appreciation that cholestasis can be an important component of AH as well. For example, a retrospective study of over 4,000 patients hospitalized for liver disease in Shanghai found that 16% of AH patients had cholestasis. (42) In another study, elevated ALP was found to be an independent predictor of increased mortality in patients with AH. (5) In a study that reported a histological scoring system to determine severity of AH, presence of cholestasis was found to be an independent predictor of increased mortality. (6) In another study, the microRNA profile of AH patients was analyzed and found to reflect changes observed in cholestatic liver diseases. (43) These findings collectively suggest that cholestasis is a frequent complication of AH and may even portend a worse outcome. As is the case in the cholestasis of sepsis, it is possible, and perhaps likely, that at least some of the cholestasis that occurs in AH is attributed to impaired secretion by hepatocytes. However, by demonstrating a loss of ITPR3 in cholangiocytes from these patients, our findings provide evidence that bile duct abnormalities may contribute to this complication. The transcription factor, Nrf2, appears to be responsible for decreased cholangiocyte ITPR3 expression in a number of cholangiopathies, (14) so it is notable that Nrf2 expression was not increased in bile ducts of patients with AH. This suggests that multiple, distinct signaling pathways may converge to decrease ITPR3 expression in cholangiocytes. Future work will be needed to understand the range of mechanisms by which ITPR3 expression is regulated in cholangiocytes and to fully define the downstream effects that result from this.
